ORKA
Oruka Therapeutics, Inc.Healthcare·Biotechnology
$58.53
$2.2B market cap
Revenue
$0.0M
Free Cash Flow
$-46.3M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
2-Year Price History
$60.61+153.8%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -36.4 | -36.4 | -31.8 | -23.6 | -23.7 | -0.1 | 388.8 | 1.8 | 55.2 | -87.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | -34.4 | -34.4 | -29.6 | -22.6 | -22.7 | -0.1 | 337.0 | 1.9 | 54.4 | -88.7% | -- | -- |
Valuation & Metrics
Market Stats
Price$58.53
Market Cap$2.2B
Enterprise Value$1.8B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-2.1%
Dividend Yield (TTM)2.8%
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-61.4M
Free Cash Flow$-46.3M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-87.8%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares7.0M
Days to Cover2.6
Change (vs Prior)+26.3%
Need at least 2 settlement dates for chart
Employees
Headcount28
Revenue / Employee$0
Gross Profit / Employee$-2,536
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
96.1%(+82.8% YoY)
169 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
20.2%(+18.8% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.1%(-0.1% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $365M | $23.14 | +$8.3M | +$91.7M | -0.0% | $1.89T |
| VR Adviser, LLC | $203M | $21.30 | +$0 | +$0 | -2.0% | $2.68B |
| Fairmount Funds Management LLC | $182M | $23.81 | +$0 | +$16.4M | +4.2% | $1.38B |
| BlackRock, Inc.Passive | $173M | $20.66 | −$605K | +$136M | -0.2% | $5.69T |
| VIKING GLOBAL INVESTORS LP | $131M | $19.23 | +$0 | +$131M | +1.0% | $35.75B |
| Paradigm Biocapital Advisors LP | $114M | $32.97 | +$29.9M | +$114M | +1.9% | $4.69B |
| RTW INVESTMENTS, LP | $101M | $24.59 | +$0 | +$5.5M | -2.2% | $9.26B |
| Deep Track Capital, LP | $99.8M | $18.11 | −$6.2M | +$28.9M | -1.2% | $4.85B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $91.2M | $49.05 | +$91.2M | +$91.2M | — | $4.04T |
| STATE STREET CORPPassive | $79.1M | $26.74 | +$11.3M | +$74.9M | -0.2% | $2.89T |
| Remedium Capital Partners, LLC | $76.8M | $30.47 | +$650K | +$76.8M | +38.8% | $281M |
| PERCEPTIVE ADVISORS LLC | $68.4M | $23.96 | −$4.0M | +$68.4M | -1.4% | $5.05B |
| Polar Capital Holdings Plc | $51.4M | $17.25 | +$3.4M | −$113K | +1.5% | $22.76B |
| CITADEL ADVISORS LLC | $49.4M | $32.06 | +$13.8M | +$49.4M | -0.4% | $138.22B |
| FRANKLIN RESOURCES INC | $49.2M | $22.25 | +$3.2M | +$13.9M | -0.2% | $403.03B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $46.8M | $19.60 | +$606K | +$29.5M | +2.3% | $1.61T |
| MERCER GLOBAL ADVISORS INC /ADV | $39.4M | $13.59 | +$2.8M | +$39.4M | -0.0% | $63.93B |
| Avidity Partners Management LP | $37.3M | $25.20 | +$4.9M | +$20.0M | -8.3% | $505M |
| PRICE T ROWE ASSOCIATES INC /MD/ | $35.7M | $21.80 | +$3.8M | +$15.5M | -0.2% | $864.93B |
| Woodline Partners LP | $28.2M | $22.84 | +$16K | +$9.0M | -0.1% | $26.43B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+1.57%
avg per quarter
Holders (ex-self)
+1.07%
excl. this stock
Buyers (this Q)
+2.40%
125 buyers · $0.77B in
Sellers (this Q)
-0.16%
32 sellers · $-0.14B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+34.6%
how holders react when this stock falls
On quiet Qs
+11.6%
−10% to +10% baseline
On rallies (+10%+)
+3.5%
how they react when this stock rises
Holders' portfolio flow this Q
+1.4%
inflows — adds are organic
Sellers' portfolio flow this Q
+3.6%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.0%
Holder mid (any stock)
-3.4%
Holder rally (any stock)
-4.0%
Biggest decreases this quarter
Commodore Capital LPexited−$53.1MAvoro Capital Advisors LLCexited−$40.4MBlackstone Group L.P.exited−$35.3MPoint72 Asset Management, L.P.exited−$18.2MAffinity Asset Advisors, LLC−$14.8Mα+0.4Deep Track Capital, LP−$6.2Mα-1.2PERCEPTIVE ADVISORS LLC−$4.0Mα-1.4BRAIDWELL LPexited−$2.6MD. E. Shaw & Co., Inc.exited−$2.3MMILLENNIUM MANAGEMENT LLCexited−$1.8M
New buyers this quarter
Top-5 holders · 41.3%
FMR LLC--
VR Adviser, LLC--
Fairmount Funds Management LLC--
BlackRock, Inc.--
VIKING GLOBAL INVESTORS LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC7.4MVR Adviser, LLC4.1MFairmount Funds Management LLC3.7MVIKING GLOBAL INVESTORS LP2.7MParadigm Biocapital Advisors LP2.3MRTW INVESTMENTS, LP2.1MDeep Track Capital, LP2.0MRemedium Capital Partners, LLC1.6MPERCEPTIVE ADVISORS LLC1.4MCommodore Capital LP—
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| GMAB | Genmab A/S | 3 | 212.40× |
| JBIO | Jade Biosciences, Inc. | 5 | 196.67× |
| DMRA | Galecto, Inc. | 4 | 157.33× |
| CAPR | Capricor Therapeutics, Inc. | 3 | 132.75× |
| SYRE | Spyre Therapeutics, Inc. | 6 | 124.94× |
| MANE | Veradermics, Incorporated | 3 | 118.00× |
| IMVT | Immunovant, Inc. | 4 | 108.92× |
| VIR | Vir Biotechnology, Inc. | 3 | 106.20× |
| MLTX | MoonLake Immunotherapeutics | 3 | 96.55× |
| ZBIO | Zenas BioPharma, Inc. | 3 | 96.55× |
| NUVL | Nuvalent, Inc. | 4 | 94.40× |
| PCVX | Vaxcyte, Inc. | 6 | 88.50× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (9 analysts)$130.4412290.0%
Last Year (15 analysts)$99.476990.0%
Current Price$58.53
Analyst Ratings
9
Buy: 9Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$9.67M
15 txns · 6 insiders · 184,388 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | SELL | Dambkowski Carl | director | 105,000 | $58.97 | $6.19M | $4.35M |
| 2026-05-18 | SELL | Agarwal Arjun | officer: Senior Vice President, Finance | 10,290 | $59.07 | $608K | $969K |
| 2026-05-15 | SELL | Goncalves Joana | officer: Chief Medical Officer | 7,000 | $61.85 | $433K | $2.06M |
| 2026-05-01 | SELL | Sandler Laura Lee | officer: Chief Operating Officer | 5,000 | $63.88 | $319K | $15.14M |
| 2026-04-15 | SELL | Goncalves Joana | officer: Chief Medical Officer | 7,000 | $66.12 | $463K | $2.21M |
| 2026-03-16 | SELL | Agarwal Arjun | officer: Senior Vice President, Finance | 395 | $41.30 | $16K | $779K |
| 2026-03-16 | SELL | Goncalves Joana | officer: Chief Medical Officer | 7,641 | $40.91 | $313K | $1.37M |
| 2026-03-16 | SELL | Klein Lawrence Otto | director, officer: Chief Executive Officer | 1,729 | $41.30 | $71K | $38.30M |
| 2026-03-16 | SELL | Quinlan Paul T | officer: General Counsel | 733 | $41.30 | $30K | $1.31M |
| 2026-03-16 | SELL | Sandler Laura Lee | officer: Chief Operating Officer | 600 | $41.30 | $25K | $9.79M |
| 2026-03-02 | SELL | Sandler Laura Lee | officer: Chief Operating Officer | 5,000 | $33.56 | $168K | $7.97M |
| 2026-02-17 | SELL | Goncalves Joana | officer: Chief Medical Officer | 7,000 | $32.37 | $227K | $1.10M |
| 2026-01-15 | SELL | Goncalves Joana | officer: Chief Medical Officer | 7,000 | $31.81 | $223K | $48K |
| 2026-01-02 | SELL | Sandler Laura Lee | officer: Chief Operating Officer | 13,000 | $28.52 | $371K | $5.85M |
| 2025-12-19 | SELL | Goncalves Joana | officer: Chief Medical Officer | 7,000 | $30.61 | $214K | $46K |
Order Flow (FINRA, ~3w lag)
10.5%retail-2.6pp
39.4%dark+5.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.